Price movement over the last 24 hours
Alcon AG vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while YieldMax Universe Fund of Option Income ETFs trades at $7.84. The key difference: Alcon AG pays a 0.54% dividend while YieldMax Universe Fund of Option Income ETFs pays none, and Alcon AG is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| ALC | YMAX | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $92.22 | $14.00 |
52-Week Low | $62.02 | $7.51 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
YMAX trades at $8.09, up 2.15% with a bearish technical signal from moving averages. The ETF generates high income through weekly distributions, though recent analysis suggests distributions include significant return of capital. Technical indicators show mixed signals with RSI at 73.39 suggesting overbought conditions while ADX indicates weakening trend strength.
YMAX offers high yield potential but faces challenges from its complex options strategy and expense structure. The fund's 1.33% total expense ratio and dependence on market volatility create headwinds for long-term capital appreciation. Investors should weigh the high income against potential NAV erosion from return of capital distributions.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →